{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:22:00Z","timestamp":1783606920419,"version":"3.55.0"},"reference-count":65,"publisher":"Bioscientifica","issue":"6","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:p>Bone metastasis is a leading cause of death in prostate cancer (PC) patients. Although androgen deprivation therapy (ADT) combined with novel androgen-targeted agents constitutes the cornerstone of systemic treatment, its efficacy is limited. We investigated the adrenal contribution to promoting progression of castration-resistant PC (CRPC) within bone using a preclinical intratibial xenograft model (VCaP, 22Rv1, and LNCaP cells). Mice underwent orchiectomy (ORX) to mimic ADT, with or without adrenalectomy (ORX + ADX) to eliminate adrenal contribution. A significant increase in bone mineral density (BMD) was observed in tumor-grafted tibiae in ORX-treated mice compared with controls (P &amp;lt; 0.001), indicating a strong tumor-induced sclerotic response. In contrast, ORX + ADX reduced tumor take rate by approximately 50% and decreased tumor-induced BMD by over 80% (P &amp;lt; 0.001). Transcriptomic analysis revealed that ADX downregulated tumor-induced transcripts in bone by over 90%, including osteogenic (Lox, Sparcl1, Bmp2, Postn, and Col1a1) and pro-angiogenic (Bmper, Pecam-1, and Esam) signatures. In addition, BMP, PI3K\/Akt, and ERK1\/2 signaling pathways were associated with the tumor-induced bone response. Both high serum progesterone and intratumoral levels of dihydrotestosterone (DHT) were associated with the sclerotic bone phenotype. ADX markedly reduced intratumoral DHT and downregulated glycolytic genes (HK2, PFK2, and LDHA) and secretory proteins expressed by the tumor, including stanniocalcin 2, potentially mediating paracrine effects in the sclerotic bone response. Altogether, these findings highlight the critical role of adrenal-dependent androgen synthesis, particularly via progesterone, in driving the sclerotic CRPC in bone. Our findings suggest that a comprehensive blockade of adrenal contribution is essential to prevent the sclerotic bone response associated with CRPC.<\/jats:p>","DOI":"10.1530\/erc-25-0309","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T15:43:07Z","timestamp":1779118987000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":0,"title":["Adrenal-derived factors drive progression of sclerotic prostate cancer in bone"],"prefix":"10.1530","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8673-1247","authenticated-orcid":true,"given":"Malin","family":"Hagberg Thulin","sequence":"first","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Li","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanna","family":"Abrahamsson","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Landin","sequence":"additional","affiliation":[{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2082-4886","authenticated-orcid":true,"given":"Karin","family":"Horkeby","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyao","family":"Wu","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie K","family":"Lagerquist","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claes","family":"Ohlsson","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8953-1734","authenticated-orcid":true,"given":"Matti","family":"Poutanen","sequence":"additional","affiliation":[{"name":"1"},{"name":"4"},{"name":"5"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"2026070909474740100_bib1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"2026070909474740100_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104287","article-title":"High intratumoral dihydrotestosterone is associated with antiandrogen resistance in VCaP prostate cancer xenografts in castrated mice","volume":"25","author":"Huhtaniemi","year":"2022","journal-title":"iScience"},{"key":"2026070909474740100_bib3","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/cncr.28485","article-title":"No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period","volume":"120","author":"Wu","year":"2014","journal-title":"Cancer"},{"key":"2026070909474740100_bib4","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.urolonc.2017.01.020","article-title":"Navigating the evolving therapeutic landscape in advanced prostate cancer","volume":"35S","author":"Crawford","year":"2017","journal-title":"Urol Oncol"},{"key":"2026070909474740100_bib5","doi-asserted-by":"crossref","first-page":"T19","DOI":"10.1530\/ERC-21-0098","article-title":"Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer","volume":"28","author":"Mitsiades","year":"2021","journal-title":"Endocr Relat Cancer"},{"key":"2026070909474740100_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3835(02)00413-5","article-title":"The role of androgens and the androgen receptor in prostate cancer","volume":"187","author":"Debes","year":"2002","journal-title":"Cancer Lett"},{"key":"2026070909474740100_bib7","doi-asserted-by":"crossref","first-page":"8253","DOI":"10.1200\/JCO.2005.03.4777","article-title":"Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis","volume":"23","author":"Scher","year":"2005","journal-title":"J Clin Oncol"},{"key":"2026070909474740100_bib8","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1210\/jc.2006-0968","article-title":"Persistent intraprostatic androgen concentrations after medical castration in healthy men","volume":"91","author":"Page","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070909474740100_bib9","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","article-title":"Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth","volume":"68","author":"Montgomery","year":"2008","journal-title":"Cancer Res"},{"key":"2026070909474740100_bib10","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1158\/0008-5472.CAN-05-4000","article-title":"Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer","volume":"66","author":"Stanbrough","year":"2006","journal-title":"Cancer Res"},{"key":"2026070909474740100_bib11","doi-asserted-by":"crossref","first-page":"6407","DOI":"10.1158\/0008-5472.CAN-07-5997","article-title":"Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer","volume":"68","author":"Locke","year":"2008","journal-title":"Cancer Res"},{"key":"2026070909474740100_bib12","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0140-6736(10)60172-9","article-title":"Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1\u20132 study","volume":"375","author":"Scher","year":"2010","journal-title":"Lancet"},{"key":"2026070909474740100_bib13","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"2026070909474740100_bib14","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/j.1464-410X.2005.05821.x","article-title":"Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer","volume":"96","author":"Attard","year":"2005","journal-title":"BJU Int"},{"key":"2026070909474740100_bib15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"2026070909474740100_bib16","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"2026070909474740100_bib17","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"key":"2026070909474740100_bib18","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1001\/jamaoncol.2017.5808","article-title":"Radiographic progression-free survival as a clinically meaningful end point in metastatic castration-resistant prostate cancer: the PREVAIL randomized clinical trial","volume":"4","author":"Rathkopf","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026070909474740100_bib19","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2014.55.3875","article-title":"Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results","volume":"33","author":"Morris","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026070909474740100_bib20","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/S1470-2045(12)70473-4","article-title":"Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial","volume":"13","author":"Logothetis","year":"2012","journal-title":"Lancet Oncol"},{"key":"2026070909474740100_bib21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","article-title":"Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study","volume":"71","author":"Beer","year":"2017","journal-title":"Eur Urol"},{"key":"2026070909474740100_bib22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00000658-197401000-00004","article-title":"Current status of bilateral adrenalectomy or advanced prostatic carcinoma","volume":"179","author":"Bhanalaph","year":"1974","journal-title":"Ann Surg"},{"key":"2026070909474740100_bib23","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/1097-0142(197204)29:4<941::AID-CNCR2820290440>3.0.CO;2-L","article-title":"Adrenalectomy and hypophysectomy in advanced prostatic carcinoma","volume":"29","author":"Reynoso","year":"1972","journal-title":"Cancer"},{"key":"2026070909474740100_bib24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0022-5347(17)60659-1","article-title":"Bilateral adrenalectomy for advanced prostatic carcinoma","volume":"108","author":"Schoonees","year":"1972","journal-title":"J Urol"},{"key":"2026070909474740100_bib25","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.3390\/cancers15205047","article-title":"Castration-resistant prostate cancer: from uncovered resistance mechanisms to current treatments","volume":"15","author":"Le","year":"2023","journal-title":"Cancers"},{"key":"2026070909474740100_bib26","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10555-014-9494-4","article-title":"Integrating new discoveries into the \u201cvicious cycle\u201d paradigm of prostate to bone metastases","volume":"33","author":"Cook","year":"2014","journal-title":"Cancer Metastasis Rev"},{"key":"2026070909474740100_bib27","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.eururo.2013.01.007","article-title":"Association between use of beta-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease","volume":"65","author":"Grytli","year":"2014","journal-title":"Eur Urol"},{"key":"2026070909474740100_bib28","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqac001","article-title":"Comprehensive sex steroid profiling in multiple tissues reveals novel insights in sex steroid distribution in Male mice","volume":"163","author":"Collden","year":"2022","journal-title":"Endocrinology"},{"key":"2026070909474740100_bib29","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1210\/en.2014-1890","article-title":"Measurement of a comprehensive sex steroid profile in rodent serum by high-sensitive gas chromatography-tandem mass spectrometry","volume":"156","author":"Nilsson","year":"2015","journal-title":"Endocrinology"},{"key":"2026070909474740100_bib30","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"2026070909474740100_bib31","doi-asserted-by":"crossref","first-page":"D258","DOI":"10.1093\/nar\/gkh036","article-title":"The gene ontology (GO) database and informatics resource","volume":"32","author":"Harris","year":"2004","journal-title":"Nucleic Acids Res"},{"key":"2026070909474740100_bib32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/nar\/28.1.27","article-title":"KEGG: kyoto encyclopedia of genes and genomes","volume":"28","author":"Kanehisa","year":"2000","journal-title":"Nucleic Acids Res"},{"key":"2026070909474740100_bib33","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS"},{"key":"2026070909474740100_bib34","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nature13229","article-title":"Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer","volume":"510","author":"Asangani","year":"2014","journal-title":"Nature"},{"key":"2026070909474740100_bib35","doi-asserted-by":"crossref","first-page":"D7","DOI":"10.1093\/nar\/gkv1290","article-title":"Database resources of the National Center for Biotechnology Information","volume":"44","author":"Coordinators","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"2026070909474740100_bib36","article-title":"Regulators of androgen action resource: a one-stop shop for the comprehensive study of androgen receptor action","volume":"2016","author":"DePriest","year":"2016","journal-title":"Database"},{"key":"2026070909474740100_bib37","doi-asserted-by":"crossref","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","article-title":"The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest","volume":"51","author":"Szklarczyk","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"2026070909474740100_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0960-0760(00)00131-X","article-title":"Pregnenolone stimulates LNCaP prostate cancer cell growth via the mutated androgen receptor","volume":"75","author":"Grigoryev","year":"2000","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2026070909474740100_bib39","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.mce.2015.11.013","article-title":"Osteoblasts promote castration-resistant prostate cancer by altering intratumoral steroidogenesis","volume":"422","author":"Hagberg Thulin","year":"2016","journal-title":"Mol Cell Endocrinol"},{"key":"2026070909474740100_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019059","article-title":"Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival","volume":"6","author":"Hornberg","year":"2011","journal-title":"PLoS One"},{"key":"2026070909474740100_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114530","article-title":"The molecular signature of the stroma response in prostate cancer-induced osteoblastic bone metastasis highlights expansion of hematopoietic and prostate epithelial stem cell niches","volume":"9","author":"Ozdemir","year":"2014","journal-title":"PLoS One"},{"key":"2026070909474740100_bib42","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.3390\/cancers12123786","article-title":"Stroma transcriptomic and proteomic profile of prostate cancer metastasis xenograft models reveals prognostic value of stroma signatures","volume":"12","author":"Karkampouna","year":"2020","journal-title":"Cancers"},{"key":"2026070909474740100_bib43","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40364-025-00745-7","article-title":"Focal adhesion in the tumour metastasis: from molecular mechanisms to therapeutic targets","volume":"13","author":"Liu","year":"2025","journal-title":"Biomark Res"},{"key":"2026070909474740100_bib44","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1038\/emboj.2011.158","article-title":"The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis","volume":"30","author":"Massie","year":"2011","journal-title":"EMBO J"},{"key":"2026070909474740100_bib45","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/s41416-021-01435-5","article-title":"Metabolic reprogramming in prostate cancer","volume":"125","author":"Ahmad","year":"2021","journal-title":"Br J Cancer"},{"key":"2026070909474740100_bib46","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"2026070909474740100_bib47","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1073\/pnas.1816391116","article-title":"Elucidating cancer metabolic plasticity by coupling gene regulation with metabolic pathways","volume":"116","author":"Jia","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026070909474740100_bib48","doi-asserted-by":"crossref","first-page":"5433","DOI":"10.1158\/1078-0432.CCR-18-1229","article-title":"The proteome of prostate cancer bone metastasis reveals heterogeneity with prognostic implications","volume":"24","author":"Iglesias-Gato","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026070909474740100_bib49","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0303-7207(98)00163-4","article-title":"Molecular cloning and characterization of stanniocalcin-related protein","volume":"146","author":"DiMattia","year":"1998","journal-title":"Mol Cell Endocrinol"},{"key":"2026070909474740100_bib50","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bbrc.2021.03.067","article-title":"The novel prognostic risk factor STC2 can regulate the occurrence and progression of osteosarcoma via the glycolytic pathway","volume":"554","author":"Yu","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"2026070909474740100_bib51","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1349-7006.2009.01117.x","article-title":"Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer","volume":"100","author":"Tamura","year":"2009","journal-title":"Cancer Sci"},{"key":"2026070909474740100_bib52","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.bbrc.2020.01.060","article-title":"STC2 modulates ERK1\/2 signaling to suppress adipogenic differentiation of human bone marrow mesenchymal stem cells","volume":"524","author":"Ma","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"2026070909474740100_bib53","doi-asserted-by":"crossref","first-page":"5653","DOI":"10.3892\/mmr.2016.5951","article-title":"Stanniocalcin 2 improved osteoblast differentiation via phosphorylation of ERK","volume":"14","author":"Zhou","year":"2016","journal-title":"Mol Med Rep"},{"key":"2026070909474740100_bib54","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1016\/j.ajpath.2018.07.029","article-title":"Adrenals contribute to growth of castration-resistant VCaP prostate cancer xenografts","volume":"188","author":"Huhtaniemi","year":"2018","journal-title":"Am J Pathol"},{"key":"2026070909474740100_bib55","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1158\/1078-0432.CCR-18-1431","article-title":"Contribution of adrenal glands to intratumor androgens and growth of castration-resistant prostate cancer","volume":"25","author":"Mostaghel","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2026070909474740100_bib56","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/s41568-023-00609-y","article-title":"Targeting sex steroid biosynthesis for breast and prostate cancer therapy","volume":"23","author":"Poutanen","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"2026070909474740100_bib57","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqad103","article-title":"Dietary progesterone contributes to intratissue levels of progesterone in Male mice","volume":"164","author":"Collden","year":"2023","journal-title":"Endocrinology"},{"key":"2026070909474740100_bib58","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9840962","article-title":"Prostate osteoblast-like cells: a reliable prognostic marker of bone metastasis in prostate cancer patients","volume":"2018","author":"Scimeca","year":"2018","journal-title":"Contrast Media Mol Imaging"},{"key":"2026070909474740100_bib59","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s10555-013-9480-2","article-title":"Bone-targeting agents in prostate cancer","volume":"33","author":"Suzman","year":"2014","journal-title":"Cancer Metastasis Rev"},{"key":"2026070909474740100_bib60","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1530\/JME-17-0076","article-title":"Sex dimorphic regulation of osteoprogenitor progesterone in bone stromal cells","volume":"59","author":"Kot","year":"2017","journal-title":"J Mol Endocrinol"},{"key":"2026070909474740100_bib61","article-title":"Inhibiting 3betaHSD1 to eliminate the oncogenic effects of progesterone in prostate cancer","volume":"3","author":"Hou","year":"2022","journal-title":"Cell Rep Med"},{"key":"2026070909474740100_bib62","article-title":"Targeted inhibition of CYP11A1 in castration-resistant prostate cancer","volume":"3","author":"Fizazi","year":"2024","journal-title":"NEJM Evid"},{"key":"2026070909474740100_bib63","doi-asserted-by":"crossref","first-page":"10139","DOI":"10.1073\/pnas.1019441108","article-title":"Structural basis for pregnenolone biosynthesis by the mitochondrial monooxygenase system","volume":"108","author":"Strushkevich","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026070909474740100_bib64","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1158\/1535-7163.MCT-22-0115","article-title":"First-in-Class small molecule to inhibit CYP11A1 and steroid hormone biosynthesis","volume":"21","author":"Karimaa","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"2026070909474740100_bib65","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1186\/s12967-025-06644-7","article-title":"Beta-blockers prolong response to androgen deprivation therapy in prostate cancer through modulation of the neuro-immuno-oncology axis","volume":"23","author":"Thulin","year":"2025","journal-title":"J Transl Med"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/33\/6\/ERC-25-0309.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/33\/6\/ERC-25-0309.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0309\/520172\/erc-25-0309.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0309\/520172\/erc-25-0309.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:47:59Z","timestamp":1783604879000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/33\/6\/e250309\/77615\/Adrenal-derived-factors-drive-progression-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":65,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-25-0309","relation":{},"ISSN":["1479-6821","1351-0088"],"issn-type":[{"value":"1479-6821","type":"electronic"},{"value":"1351-0088","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"article-number":"e250309"}}